A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass
Top Cited Papers
- 31 January 2009
- journal article
- clinical trial
- Published by Elsevier BV in Gynecologic Oncology
- Vol. 112 (1), 40-46
- https://doi.org/10.1016/j.ygyno.2008.08.031
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Effect of Surgeon Specialty on Processes of Care and Outcomes for Ovarian Cancer PatientsJNCI Journal of the National Cancer Institute, 2006
- Improved short-term survival for advanced ovarian, tubal, and peritoneal cancer patients operated at teaching hospitalsInternational Journal of Gynecologic Cancer, 2006
- Surgery by consultant gynecologic oncologists improves survival in patients with ovarian carcinomaCancer, 2005
- Who should operate on patients with ovarian cancer? An evidence-based reviewGynecologic Oncology, 2005
- Human Epididymis Protein 4 (HE4) Is a Secreted Glycoprotein that Is Overexpressed by Serous and Endometrioid Ovarian CarcinomasCancer Research, 2005
- A Population-Based Study of Patterns of Care for Ovarian Cancer: Who Is Seen by a Gynecologic Oncologist and Who Is Not?Gynecologic Oncology, 2002
- Stage IV Ovarian Cancer: Impact of Surgical Debulking1Gynecologic Oncology, 1997
- Prospective Multicenter Study on CA 125 in Postmenopausal Pelvic MassesGynecologic Oncology, 1994
- A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancerBJOG: An International Journal of Obstetrics and Gynaecology, 1990
- A Radioimmunoassay Using a Monoclonal Antibody to Monitor the Course of Epithelial Ovarian CancerThe New England Journal of Medicine, 1983